The field of neurodegenerative dementias, particularly Alzheimer disease (AD), has been limited by challenges in accurate diagnosis, but has recently been potentially revolutionized by the development of imaging and cerebrospinal fluid (CSF) biomarkers. These biomarkers have influenced the diagnostic evaluation of symptomatic patients with cognitive impairment or dementia, particularly in dementia subspecialty practice. The primary biomarker modalities include magnetic resonance imaging (MRI), positron emission tomography (PET), and CSF.
Wolk D, Salloway S, Dickerson B. Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test. JAMA. 2019;321(23):2289–2291. doi:10.1001/jama.2019.7534
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: